Comprehensive review of CBD for epilepsy: from mechanisms to clinical trial results
A comprehensive review of pharmaceutical CBD for epilepsy synthesized data from four pivotal RCTs showing significant seizure reduction in Dravet and Lennox-Gastaut syndromes, with notable drug interactions.
Quick Facts
What This Study Found
Pharmaceutical CBD (Epidiolex) was approved based on four pivotal RCTs enrolling 154 Dravet and 396 Lennox-Gastaut syndrome patients. Both 10 and 20 mg/kg/day doses met primary endpoints for seizure reduction. Key adverse effects included somnolence, decreased appetite, diarrhea, and liver enzyme elevations (mainly with concomitant valproate). The CBD-clobazam interaction via CYP2C19 likely contributes to both efficacy and side effects.
Key Numbers
4 pivotal RCTs; 154 DS + 396 LGS patients; CBD 10-20 mg/kg/day; oral bioavailability 6%; metabolized by CYP3A4 and CYP2C19; liver enzyme elevations mainly with valproate co-administration.
How They Did This
Comprehensive narrative review covering CBD pharmacology, mechanisms of action, pharmacokinetics, drug interactions, and pivotal clinical trial data for epilepsy indications.
Why This Research Matters
This review provides the most complete picture of pharmaceutical CBD for epilepsy in one place, from molecular mechanisms through clinical trial results, helping clinicians understand both the benefits and the complexities.
The Bigger Picture
CBD represents a genuine pharmaceutical success story: from folk remedy to rigorous clinical trials to regulatory approval. Understanding its drug interactions is essential because most epilepsy patients take multiple medications.
What This Study Doesn't Tell Us
Narrative review format; pivotal trials were industry-sponsored; long-term data beyond trial periods are limited; results apply to pharmaceutical-grade CBD (Epidiolex) and may not generalize to consumer products.
Questions This Raises
- ?Will CBD prove effective for other epilepsy syndromes beyond DS and LGS?
- ?Can the clobazam interaction be managed to optimize both efficacy and tolerability?
Trust & Context
- Key Stat:
- 4 RCTs: both 10 and 20 mg/kg/day CBD significantly reduced seizures
- Evidence Grade:
- Strong: synthesizes data from four pivotal double-blind RCTs that led to regulatory approval.
- Study Age:
- Published 2020.
- Original Title:
- Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects.
- Published In:
- Neuropsychiatric disease and treatment, 16, 381-396 (2020)
- Authors:
- Morano, Alessandra(3), Fanella, Martina, Albini, Mariarita, Cifelli, Pierangelo, Palma, Eleonora, Giallonardo, Anna Teresa, Di Bonaventura, Carlo
- Database ID:
- RTHC-02730
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Which epilepsy syndromes does CBD treat?
Pharmaceutical CBD (Epidiolex) is approved for Dravet syndrome and Lennox-Gastaut syndrome based on four pivotal RCTs. It is also being investigated for tuberous sclerosis complex.
What are the main drug interactions to watch for?
CBD strongly inhibits CYP2C19, which raises clobazam levels (potentially increasing both efficacy and somnolence). Liver enzyme elevations occur mainly in patients also taking valproate.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02730APA
Morano, Alessandra; Fanella, Martina; Albini, Mariarita; Cifelli, Pierangelo; Palma, Eleonora; Giallonardo, Anna Teresa; Di Bonaventura, Carlo. (2020). Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects.. Neuropsychiatric disease and treatment, 16, 381-396. https://doi.org/10.2147/NDT.S203782
MLA
Morano, Alessandra, et al. "Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects.." Neuropsychiatric disease and treatment, 2020. https://doi.org/10.2147/NDT.S203782
RethinkTHC
RethinkTHC Research Database. "Cannabinoids in the Treatment of Epilepsy: Current Status an..." RTHC-02730. Retrieved from https://rethinkthc.com/research/morano-2020-cannabinoids-in-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.